Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 375 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Prize winning early detection research October 7, 2021 Five Questions With…Stephen. May 5, 2022 Study Finds Possible New Treatment for Metastatic Breast Cancer That Has... January 29, 2022 Persistent Poverty Linked to Increased Risk of Dying from Cancer November 19, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib... GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced,...
